CH650154A5 - Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. - Google Patents
Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. Download PDFInfo
- Publication number
- CH650154A5 CH650154A5 CH4957/81A CH495781A CH650154A5 CH 650154 A5 CH650154 A5 CH 650154A5 CH 4957/81 A CH4957/81 A CH 4957/81A CH 495781 A CH495781 A CH 495781A CH 650154 A5 CH650154 A5 CH 650154A5
- Authority
- CH
- Switzerland
- Prior art keywords
- bone marrow
- fraction
- mrf
- medium
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 210000000988 bone and bone Anatomy 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title description 3
- 210000002798 bone marrow cell Anatomy 0.000 claims description 78
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 49
- 210000001185 bone marrow Anatomy 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 206010068051 Chimerism Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 230000000735 allogeneic effect Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000002211 ultraviolet spectrum Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 33
- 239000006228 supernatant Substances 0.000 description 26
- 230000005855 radiation Effects 0.000 description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 229940104230 thymidine Drugs 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 14
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 14
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 238000010322 bone marrow transplantation Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 208000037921 secondary disease Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- MJQHZNBUODTQTK-WKGBVCLCSA-N (2s,3r,4s,5r,6r)-2-[[(1s,3s,4s,5s,8r)-3-[(2s,3r,4s,5s,6r)-2-[[(1s,3r,4s,5s,8r)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5- Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H]2OC[C@@H]1O[C@@H](O[C@@H]1[C@H]([C@H](O[C@H]3[C@H]4OC[C@@H]3O[C@@H](O)[C@H]4O)O[C@H](CO)[C@@H]1O)O)[C@H]2O MJQHZNBUODTQTK-WKGBVCLCSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- HPGXYQZKIMWRAM-UHFFFAOYSA-N 4-ethylmorpholin-4-ium;acetate Chemical compound CC(O)=O.CCN1CCOCC1 HPGXYQZKIMWRAM-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7940392 | 1979-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH650154A5 true CH650154A5 (de) | 1985-07-15 |
Family
ID=10509350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4957/81A CH650154A5 (de) | 1979-11-22 | 1980-11-21 | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4540574A (enExample) |
| JP (1) | JPS56501525A (enExample) |
| AU (1) | AU544136B2 (enExample) |
| CH (1) | CH650154A5 (enExample) |
| DK (1) | DK312081A (enExample) |
| FR (1) | FR2469926A1 (enExample) |
| GB (1) | GB2074864B (enExample) |
| SE (1) | SE8104458L (enExample) |
| WO (1) | WO1981001367A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2569110B1 (fr) * | 1984-08-17 | 1987-09-25 | Ionescu Pantelimon Dumitru | Sang animal et moelle osseuse animale decancerisants, transfusibles aux hommes, procede et appareil pour leur preparation |
| JPH0753667B2 (ja) * | 1985-08-09 | 1995-06-07 | 新技術開発事業団 | 骨髄移植療法補助剤 |
| US5482924A (en) * | 1991-05-06 | 1996-01-09 | Centre National De La Recherche | Proteinaceous compositions having an activity on erythropoiesis |
| MD838G2 (ro) * | 1992-07-21 | 1998-09-30 | Alexandr Nicolaenco | Remediu biologic activ cu proprietate imunomodulatoare, procedeu de obţinere a lui, preparat pe baza lui şi procedeu de normalizare a stării fiziologice a omului şi animalelor |
| CA2149146A1 (en) * | 1992-07-21 | 1994-02-03 | Dmitry Borislavovich Shorokh | Biologically active agent having immuno-modulating properties, method for its obtaining and pharmaceutical preparation based on it |
| US5843449A (en) * | 1996-03-25 | 1998-12-01 | Akzo Nobel N.V. | Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases |
| RU2152219C1 (ru) * | 1998-04-08 | 2000-07-10 | Научно-Исследовательский Институт Трансплантологии И Искусственных Органов | Пептиды, обладающие иммуностимулирующей активностью, способ их получения, лекарственный препарат на их основе спленопид и его применение |
| RU2232584C1 (ru) * | 2003-02-27 | 2004-07-20 | Гурьянов Сергей Алексеевич | Способ получения миелопида |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1345565A (fr) * | 1962-01-19 | 1963-12-13 | Rolland Lab A | Procédé pour l'obtention d'extraits totaux plus généralement orginaires de tissus viants |
| NL6405724A (enExample) * | 1963-05-23 | 1964-11-24 | ||
| GB1086689A (en) * | 1964-12-01 | 1967-10-11 | Alkliam Chemicals Ltd | Pharmaceutically active extracts of bone marrow |
| US3526697A (en) * | 1966-10-06 | 1970-09-01 | Nevada Pharm Inc | Therapeutic method |
| FR2112112B1 (enExample) * | 1970-11-04 | 1974-09-20 | Rusin Marina | |
| US4136170A (en) * | 1975-11-21 | 1979-01-23 | Andre Thomas | Method of extracting a hyperglycemic factor |
| DE2961660D1 (en) * | 1978-05-03 | 1982-02-18 | Yves Marie Frank Souron | Wound-healing product extracted from animal bone marrow |
-
1980
- 1980-11-21 WO PCT/EP1980/000136 patent/WO1981001367A1/de not_active Ceased
- 1980-11-21 US US06/279,994 patent/US4540574A/en not_active Expired - Fee Related
- 1980-11-21 FR FR8024835A patent/FR2469926A1/fr active Granted
- 1980-11-21 AU AU64869/80A patent/AU544136B2/en not_active Ceased
- 1980-11-21 CH CH4957/81A patent/CH650154A5/de not_active IP Right Cessation
- 1980-11-21 GB GB8120895A patent/GB2074864B/en not_active Expired
- 1980-11-21 JP JP50000681A patent/JPS56501525A/ja active Pending
-
1981
- 1981-07-13 DK DK312081A patent/DK312081A/da not_active Application Discontinuation
- 1981-07-20 SE SE8104458A patent/SE8104458L/ not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56501525A (enExample) | 1981-10-22 |
| FR2469926B1 (enExample) | 1983-12-30 |
| SE8104458L (sv) | 1981-07-20 |
| GB2074864B (en) | 1984-08-22 |
| AU6486980A (en) | 1981-06-03 |
| DK312081A (da) | 1981-07-13 |
| WO1981001367A1 (fr) | 1981-05-28 |
| AU544136B2 (en) | 1985-05-16 |
| FR2469926A1 (fr) | 1981-05-29 |
| US4540574A (en) | 1985-09-10 |
| GB2074864A (en) | 1981-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3227262C2 (enExample) | ||
| DE3001585A1 (de) | Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen | |
| DE3306297A1 (de) | Neue glykoproteine, verfahren zu deren herstellung und therapeutische mittel, die solche glykoproteine enthalten, gegen tumore | |
| DE2458327A1 (de) | Rinder-immunoglobulin-isolierungsverfahren | |
| DE9321535U1 (de) | Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper | |
| CH650154A5 (de) | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. | |
| DE4242902A1 (de) | Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| DE69626853T2 (de) | Nicht-immunogene Blutplättchen und rote Blutzellen enthaltende Zubereitungen | |
| DE69835591T2 (de) | Induktoren für immuntoleranz | |
| DE3650139T2 (de) | Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz. | |
| DE3504940C2 (de) | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel | |
| AT395017B (de) | Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates | |
| DE2352662A1 (de) | Verfahren zur herstellung eines uebertragungsfaktors | |
| Pierpaoli et al. | Enduring allogeneic marrow engraftment via nonspecific bone-marrow-derived regulating factors (MRF) | |
| DE3737274A1 (de) | Verwendung von reinem h2a- und/oder h2b-histon als wirksubstanz zur herstellung von arzneimitteln | |
| DE69526096T2 (de) | Wachstumsregulator | |
| Roe et al. | Thalidomide and neoplasia | |
| DE3626110A1 (de) | Immunsuppressives serum | |
| DE69434256T2 (de) | Immunglobulin-Infusion bei der Xenotransplantation | |
| DE10007771A1 (de) | Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2015804A1 (de) | Verfahren zur Herstellung eines antigenen oder allergenen Extraktes | |
| DE3877102T2 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
| DE3249946C2 (de) | hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung | |
| DE3686113T2 (de) | Lymphokin, dessen herstellung und verwendungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |